Recombinant human erythropoietin biosimilar (North China Pharmaceutical Corporation)

重组人促红素生物类似药（华北制药金坦生物技术）

Report date: 2023/05/08 14:03:28

Base Information

Drug NameRecombinant human erythropoietin biosimilar (North China Pharmaceutical Corporation)
Drug Alias NameGerEPO重组人促红素生物仿制药（华北制药金坦生物技术）rhEPO (North China Pharmaceutical Corporation)济脉欣JT1801 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemiaRenal Insufficiency, Chronic
Global Approved IndicationsAnemia
Approved Indications in ChinaAnemia
Original Approved Country/TerritoryMainland China
Original Approved Date2000/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNorth China Pharmaceutical Company Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNcpc Genetech Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsAnemiaRenal Insufficiency, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeB03XA01
Related LinksN/A